Cargando…
Antitumour imidazotetrazines: past, present… and future?
It is 40 years since the publication of the patent that announced the imidazotetrazines temozolomide and mitozolomide to the world and 30 since the discovery that they function as prodrugs of alkyldiazonium reactive intermediates. Temozolomide combined with radiation is established as the first-line...
Autores principales: | Stevens, Malcolm F. G., Wheelhouse, Richard T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
RSC
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10549241/ https://www.ncbi.nlm.nih.gov/pubmed/37799580 http://dx.doi.org/10.1039/d3cb00076a |
Ejemplares similares
-
Antitumour imidazotetrazines, Part IX. The pharmacokinetics of mitozolomide in mice.
por: Goddard, C., et al.
Publicado: (1985) -
The Medicinal Chemistry of Imidazotetrazine Prodrugs
por: Moody, Catherine L., et al.
Publicado: (2014) -
C8-Substituted Imidazotetrazine Analogs Overcome Temozolomide Resistance by Inducing DNA Adducts and DNA Damage
por: Yang, Zhikuan, et al.
Publicado: (2019) -
Tunable Stability of Imidazotetrazines Leads to a
Potent Compound for Glioblastoma
por: Svec, Riley L., et al.
Publicado: (2018) -
Carbon monoxide separation: past, present and future
por: Ma, Xiaozhou, et al.
Publicado: (2023)